Targeted therapies: a new generation of cancer treatments

Area of Science:

• Oncology
• Pharmacology
• Internal Medicine

Background:

• Targeted therapies have revolutionized cancer treatment over the last decade.
• These therapies encompass monoclonal antibodies and small molecule inhibitors, now standard for numerous malignancies.
• They represent a shift from traditional cytotoxic chemotherapy in cancer care.

Purpose of the Study:

• To review the mechanisms of action and toxicities of targeted cancer therapies.
• To highlight the evolving role of primary care physicians in managing patients on targeted therapy.
• To discuss the implications of targeted therapy on personalized medicine and healthcare economics.

Main Methods:

• Literature review of targeted cancer therapies.
• Analysis of mechanisms of action and adverse events.
• Discussion of clinical management and future directions.

Main Results:

• Targeted therapies differ significantly from traditional chemotherapy in action and toxicity.
• Common adverse effects include rash, cardiac issues, thrombosis, hypertension, and proteinuria.
• Small molecule inhibitors undergo cytochrome P450 metabolism, leading to drug interactions.

Conclusions:

• Targeted therapies offer improved outcomes but require careful management of specific toxicities.
• Personalized treatment strategies and ongoing patient monitoring are crucial.
• Primary care physicians play an expanding role in the long-term care of cancer survivors on targeted therapies.